M5049

selective TLR7/8 inhibitor (dimer stabilizer)

in Ph. I for lupus (oral twice-daily)

from screening for TLR7/8-selective agents

J. Pharmacol. Exp. Ther., Mar. 1, 2021

EMD Serono/Merck KGaA, Billerica, MA

11. The EMD Serono/Merck KGaA toll-like receptors TLR7/TLR8 inhibitor M5049 is an oral, twice-daily anti-inflammatory agent currently in a Ph. I trial for Lupus. The molecule potently blocks both…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.